KA/EN
Register
Medicines reference
Search
Search
Product

Augmentin

Favourites

Amoxicillin + Clavulanic Acid · GlaxoSmithKline

2 forms: powder, tablet. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
228 mg/5 ml, Powder - - No label dose in the reference yet - Georgia Yes, human
In force until 08 Jul 2030
Human (Ministry of Health, RAMA)
№ რ-043538
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Augmentin 228 mg/5 ml, Powder

powder for oral suspension, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed oral treatment of a susceptible bacterial infection with exact Augmentin 228 mg/5 ml, a 7:1 human suspension without a validated dog/cat dose bridge
Not rateable
No numerical score assigned
vetman assessment

Augmentin

228 mg/5 ml, powder for oral suspension, human medicine
Assessed clinical scopeDog · Proposed oral treatment of a susceptible bacterial infection with exact Augmentin 228 mg/5 ml, a 7:1 human suspension without a validated dog/cat dose bridge · By mouth
Care settingVeterinarian-directed antimicrobial selection after diagnosis, susceptibility and exact presentation review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, human · № რ-043538 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned to this exact 7:1 suspension in dogs or cats. The prior 0.25 ml/kg row was transferred from 4:1 Synulox Drops because both contain 40 mg/ml amoxicillin, but Augmentin then supplies only 1.425 mg/kg clavulanate instead of 2.5 mg/kg. No exact-product dog/cat PK, target-animal safety, bioequivalence or clinical bridge was found. Accurate liquid measurement cannot repair an unvalidated component ratio.

The exact human label is transparent, but a product score would hide the missing veterinary bridge. The calculator is intentionally blocked; select an exact dog/cat formulation whose component ratio and regimen are validated.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection likely to be susceptible to amoxicillin/clavulanate. Obtain culture and susceptibility whenever feasible and narrow, change or stop treatment when results do not support it.
  • Exact-product boundary: Augmentin 228 mg/5 ml is a 7:1 human suspension, not 4:1 Synulox Drops. Do not transfer the Synulox 0.25 ml/kg regimen by matching amoxicillin concentration alone.
  • No dog or cat calculator dose is published. At the old 0.25 ml/kg volume, this product supplies only 1.425 mg/kg clavulanate rather than the veterinary comparator dose of 2.5 mg/kg; accurate measurement does not validate the altered ratio.
  • Give at the start of a meal to reduce gastrointestinal intolerance. Monitor appetite, vomiting and diarrhoea; severe or persistent signs, haemorrhagic diarrhoea or clinical deterioration require prompt reassessment.
  • Do not use with known penicillin, cephalosporin or other beta-lactam hypersensitivity. Urticaria, facial swelling, dyspnoea, hypotension or collapse may indicate anaphylaxis and requires immediate treatment.
  • Do not assume clavulanate is needed whenever amoxicillin is selected. Use amoxicillin alone when beta-lactamase inhibition is not clinically justified, and avoid unnecessary broad-spectrum or prolonged exposure.
  • Review concurrent bacteriostatic antimicrobials and other medication before treatment. Tetracyclines, macrolides, chloramphenicol, sulfonamides and related combinations require a specific microbiologic and clinical rationale.
  • Renal impairment may require interval or regimen review. Avoid extrapolation in severe hepatic disease, dehydration or unstable patients; monitor clinical response and relevant renal, hepatic or haematologic variables when risk or duration warrants.
  • Reconstitute exactly as the label directs, shake before every dose, refrigerate at 2–8 C, do not freeze and discard after seven days. These handling instructions do not establish a veterinary dose.
  • Pregnancy, lactation, breeding and immature-patient use require explicit veterinarian benefit-risk review. Exact-product target-animal reproductive and developmental safety data are absent.
Assessment sources
  1. Augmentin 228 suspension2024
  2. Augmentin 228 NPRA2026
  3. Augmentin 625 tablets2024
  4. Augmentin 625 SmPC2026
  5. Synulox tablets2025
  6. Synulox drops2025
  7. Clavaseptin PAR2026
  8. ISCAID pyoderma 20252025
  9. ISCAID UTI2019
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed oral treatment of a susceptible bacterial infection with exact Augmentin 228 mg/5 ml, a 7:1 human suspension without a validated dog/cat dose bridge
Not rateable
No numerical score assigned
vetman assessment

Augmentin

228 mg/5 ml, powder for oral suspension, human medicine
Assessed clinical scopeCat · Proposed oral treatment of a susceptible bacterial infection with exact Augmentin 228 mg/5 ml, a 7:1 human suspension without a validated dog/cat dose bridge · By mouth
Care settingVeterinarian-directed antimicrobial selection after diagnosis, susceptibility and exact presentation review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, human · № რ-043538 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned to this exact 7:1 suspension in dogs or cats. The prior 0.25 ml/kg row was transferred from 4:1 Synulox Drops because both contain 40 mg/ml amoxicillin, but Augmentin then supplies only 1.425 mg/kg clavulanate instead of 2.5 mg/kg. No exact-product dog/cat PK, target-animal safety, bioequivalence or clinical bridge was found. Accurate liquid measurement cannot repair an unvalidated component ratio.

The exact human label is transparent, but a product score would hide the missing veterinary bridge. The calculator is intentionally blocked; select an exact dog/cat formulation whose component ratio and regimen are validated.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection likely to be susceptible to amoxicillin/clavulanate. Obtain culture and susceptibility whenever feasible and narrow, change or stop treatment when results do not support it.
  • Exact-product boundary: Augmentin 228 mg/5 ml is a 7:1 human suspension, not 4:1 Synulox Drops. Do not transfer the Synulox 0.25 ml/kg regimen by matching amoxicillin concentration alone.
  • No dog or cat calculator dose is published. At the old 0.25 ml/kg volume, this product supplies only 1.425 mg/kg clavulanate rather than the veterinary comparator dose of 2.5 mg/kg; accurate measurement does not validate the altered ratio.
  • Give at the start of a meal to reduce gastrointestinal intolerance. Monitor appetite, vomiting and diarrhoea; severe or persistent signs, haemorrhagic diarrhoea or clinical deterioration require prompt reassessment.
  • Do not use with known penicillin, cephalosporin or other beta-lactam hypersensitivity. Urticaria, facial swelling, dyspnoea, hypotension or collapse may indicate anaphylaxis and requires immediate treatment.
  • Do not assume clavulanate is needed whenever amoxicillin is selected. Use amoxicillin alone when beta-lactamase inhibition is not clinically justified, and avoid unnecessary broad-spectrum or prolonged exposure.
  • Review concurrent bacteriostatic antimicrobials and other medication before treatment. Tetracyclines, macrolides, chloramphenicol, sulfonamides and related combinations require a specific microbiologic and clinical rationale.
  • Renal impairment may require interval or regimen review. Avoid extrapolation in severe hepatic disease, dehydration or unstable patients; monitor clinical response and relevant renal, hepatic or haematologic variables when risk or duration warrants.
  • Reconstitute exactly as the label directs, shake before every dose, refrigerate at 2–8 C, do not freeze and discard after seven days. These handling instructions do not establish a veterinary dose.
  • Pregnancy, lactation, breeding and immature-patient use require explicit veterinarian benefit-risk review. Exact-product target-animal reproductive and developmental safety data are absent.
Assessment sources
  1. Augmentin 228 suspension2024
  2. Augmentin 228 NPRA2026
  3. Augmentin 625 tablets2024
  4. Augmentin 625 SmPC2026
  5. Synulox tablets2025
  6. Synulox drops2025
  7. Clavaseptin PAR2026
  8. Feline antimicrobial consensus2025
  9. ISCAID UTI2019
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Amoxicillin40 mg/ml Clavulanic Acid5.7 mg/ml
Formulation Type
Powder
Administration route
By mouth
Manufacturer
GlaxoSmithKline · United Kingdom
Registration
Georgia Yes, human
In force until 08 Jul 2030
Human (Ministry of Health, RAMA)
№ რ-043538
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000380270, PL000380298, PL000380337, PL000380362
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose is published for this exact 7:1 suspension. Do not transfer the 0.25 ml/kg Synulox Drops regimen: at that volume this product supplies 10 mg/kg amoxicillin but only 1.425 mg/kg clavulanate, versus 2.5 mg/kg in the authorised 4:1 veterinary liquid.
625 mg, Tablet · Cat Any weight Cat Any weight No dose for this species
No feline dose is established for this exact 500/125 mg human tablet. The unit is too large for a typical feline regimen and the exact SmPC does not validate equal-dose halves.
 - Georgia Yes, human
In force until 12 Jun 2030
Human (Ministry of Health, RAMA)
№ რ-043404
Verified on: 15 Oct 2026
625 mg, Tablet · Dog 25–50 kg Dog 25–50 kg 1 tablet
1.000 whole tablet(s) every 12 hours for 25.00–50.00 kg dogs. This band spans 20 to 10 mg/kg amoxicillin; the upper exposure is reserved by the veterinary comparator for refractory respiratory infection. The exact human tablet is not an equal-dose divider.
 · 2 times daily		 2 times daily Georgia Yes, human
In force until 12 Jun 2030
Human (Ministry of Health, RAMA)
№ რ-043404
Verified on: 15 Oct 2026
625 mg, Tablet · Dog 50–100 kg Dog 50–100 kg 2 tablets
2.000 whole tablet(s) every 12 hours for 50.00–100.00 kg dogs. This band spans 20 to 10 mg/kg amoxicillin; the upper exposure is reserved by the veterinary comparator for refractory respiratory infection. The exact human tablet is not an equal-dose divider.
 · 2 times daily		 2 times daily Georgia Yes, human
In force until 12 Jun 2030
Human (Ministry of Health, RAMA)
№ რ-043404
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Augmentin 625 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Veterinarian-directed treatment of an appropriate susceptible bacterial infection in a dog whose indication-specific calculated regimen reasonably matches a whole 500/125 mg tablet
6.9/10
Situational / acceptable
vetman assessment

Augmentin

625 mg, tablet, human medicine
Assessed clinical scopeDog · Veterinarian-directed treatment of an appropriate susceptible bacterial infection in a dog whose indication-specific calculated regimen reasonably matches a whole 500/125 mg tablet · By mouth
Care settingVeterinarian-directed outpatient or inpatient antimicrobial treatment with diagnosis, susceptibility, weight and whole-unit fit reviewed
vetman score 6.9/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043404 · Verified on 15 Oct 2026 Off-label use

A defensible extra-label option only for an appropriate susceptible infection in a dog whose calculated regimen matches a whole tablet. Exact identity and the 4:1 ratio are strengths; absent canine product data, antimicrobial-stewardship limits and poor dose-unit flexibility keep it situational.

Regulatory and scientific credibility7.5/10

The exact 500/125 mg human product has current manufacturer and regulator-aligned prescribing information with composition, contraindications, interactions and subdivision limits. Current authorised veterinary 4:1 comparators verify the dog formulation concept and regimen, but Augmentin itself is not dog-labelled and exact-product canine outcome or bioequivalence data are absent.

Clinical efficacy7.5/10

Amoxicillin/clavulanate has direct authorised dog indications and controlled veterinary comparator trials, with guideline support for selected susceptible infections. Benefit is diagnosis- and susceptibility-dependent; broad empirical use, transfer of every human indication, or clavulanate where amoxicillin alone suffices is not supported.

Safety and tolerability7.0/10

The beta-lactam combination is generally well tolerated but can cause gastrointestinal effects, hypersensitivity including anaphylaxis, microbiome disruption and selection pressure. Renal impairment, pregnancy/lactation, interacting antimicrobials and previous beta-lactam reactions require review; exact-product canine safety and fragment uniformity are untested.

Clinical practicality5.0/10

Twice-daily oral dosing is familiar, but the 500/125 mg unit fits only selected large dogs and indication-specific dose points. The score line is not an equal-dose divider, so the old half-tablet band is removed; smaller dogs require another validated strength or formulation.

Full-course cost-effectiveness-

Current comparable full-course local prices were not verified.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection likely to be susceptible to amoxicillin/clavulanate. Obtain culture and susceptibility whenever feasible and narrow, change or stop treatment when results do not support it.
  • Exact-product boundary: each tablet is 500 mg amoxicillin plus 125 mg clavulanate. Do not substitute a different co-amoxiclav strength by matching only the amoxicillin number; component ratios and delivered clavulanate may differ.
  • Use only a whole tablet when the indication-specific calculated regimen fits. The line is for ease of swallowing, not equal-dose subdivision; do not restore the old half-tablet band or improvise smaller fragments.
  • Give at the start of a meal to reduce gastrointestinal intolerance. Monitor appetite, vomiting and diarrhoea; severe or persistent signs, haemorrhagic diarrhoea or clinical deterioration require prompt reassessment.
  • Do not use with known penicillin, cephalosporin or other beta-lactam hypersensitivity. Urticaria, facial swelling, dyspnoea, hypotension or collapse may indicate anaphylaxis and requires immediate treatment.
  • Do not assume clavulanate is needed whenever amoxicillin is selected. Use amoxicillin alone when beta-lactamase inhibition is not clinically justified, and avoid unnecessary broad-spectrum or prolonged exposure.
  • Review concurrent bacteriostatic antimicrobials and other medication before treatment. Tetracyclines, macrolides, chloramphenicol, sulfonamides and related combinations require a specific microbiologic and clinical rationale.
  • Renal impairment may require interval or regimen review. Avoid extrapolation in severe hepatic disease, dehydration or unstable patients; monitor clinical response and relevant renal, hepatic or haematologic variables when risk or duration warrants.
  • Do not crush or pre-divide for dose measurement. Confirm that the dog can safely swallow the whole unit and use another validated strength or formulation when it cannot.
  • Pregnancy, lactation, breeding and immature-patient use require explicit veterinarian benefit-risk review. Exact-product target-animal reproductive and developmental safety data are absent.
Assessment sources
  1. Augmentin 228 suspension2024
  2. Augmentin 228 NPRA2026
  3. Augmentin 625 tablets2024
  4. Augmentin 625 SmPC2026
  5. Synulox tablets2025
  6. Synulox drops2025
  7. Clavaseptin PAR2026
  8. ISCAID pyoderma 20252025
  9. ISCAID UTI2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Proposed oral treatment of a susceptible feline bacterial infection with exact Augmentin 625 mg, an indivisible 500/125 mg human dose unit
Not rateable
No numerical score assigned
vetman assessment

Augmentin

625 mg, tablet, human medicine
Assessed clinical scopeCat · Proposed oral treatment of a susceptible feline bacterial infection with exact Augmentin 625 mg, an indivisible 500/125 mg human dose unit · By mouth
Care settingVeterinarian-directed antimicrobial selection after diagnosis, susceptibility and exact presentation review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Yes, human · № რ-043404 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot responsibly be assigned. The exact 625 mg tablet supplies 500/125 mg and the current SmPC says its line is only to ease swallowing, not to obtain equal doses. A whole tablet is not a credible typical feline unit, while a half or smaller piece would invent an unvalidated delivered dose. Strong class evidence does not make this presentation doseable in cats.

The active combination is established in cats, but this exact large human tablet is not. Prefer a veterinary strength or liquid that can deliver the calculated component doses without relying on unequal fragments.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection likely to be susceptible to amoxicillin/clavulanate. Obtain culture and susceptibility whenever feasible and narrow, change or stop treatment when results do not support it.
  • Exact-product boundary: each tablet is 500 mg amoxicillin plus 125 mg clavulanate. Do not substitute a different co-amoxiclav strength by matching only the amoxicillin number; component ratios and delivered clavulanate may differ.
  • No feline calculator dose is published. A whole 500/125 mg tablet is not a credible typical feline unit, and the exact label does not validate a half or smaller equal dose.
  • Give at the start of a meal to reduce gastrointestinal intolerance. Monitor appetite, vomiting and diarrhoea; severe or persistent signs, haemorrhagic diarrhoea or clinical deterioration require prompt reassessment.
  • Do not use with known penicillin, cephalosporin or other beta-lactam hypersensitivity. Urticaria, facial swelling, dyspnoea, hypotension or collapse may indicate anaphylaxis and requires immediate treatment.
  • Do not assume clavulanate is needed whenever amoxicillin is selected. Use amoxicillin alone when beta-lactamase inhibition is not clinically justified, and avoid unnecessary broad-spectrum or prolonged exposure.
  • Review concurrent bacteriostatic antimicrobials and other medication before treatment. Tetracyclines, macrolides, chloramphenicol, sulfonamides and related combinations require a specific microbiologic and clinical rationale.
  • Renal impairment may require interval or regimen review. Avoid extrapolation in severe hepatic disease, dehydration or unstable patients; monitor clinical response and relevant renal, hepatic or haematologic variables when risk or duration warrants.
  • Do not crush or pre-divide for dose measurement. Confirm that the dog can safely swallow the whole unit and use another validated strength or formulation when it cannot.
  • Pregnancy, lactation, breeding and immature-patient use require explicit veterinarian benefit-risk review. Exact-product target-animal reproductive and developmental safety data are absent.
Assessment sources
  1. Augmentin 228 suspension2024
  2. Augmentin 228 NPRA2026
  3. Augmentin 625 tablets2024
  4. Augmentin 625 SmPC2026
  5. Synulox tablets2025
  6. Synulox drops2025
  7. Clavaseptin PAR2026
  8. Feline antimicrobial consensus2025
  9. ISCAID UTI2019
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Amoxicillin500 mg Clavulanic Acid125 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
GlaxoSmithKline · United Kingdom
Registration
Georgia Yes, human
In force until 12 Jun 2030
Human (Ministry of Health, RAMA)
№ რ-043404
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PL000380270, PL000380298, PL000380337, PL000380362
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified One tablet contains 500 mg amoxicillin plus 125 mg clavulanate. The line may ease swallowing but is not validated to divide the tablet into equal doses. Only whole-unit use can be considered, and only when the calculated indication-specific regimen fits.
DoseSpeciesWeightRouteFrequencySource
No dose for this species
No feline dose is established for this exact 500/125 mg human tablet. The unit is too large for a typical feline regimen and the exact SmPC does not validate equal-dose halves.
 Cat Any weight By mouth -
Augmentin 625 SmPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Augmentin 625 mg Tablets - Summary of Product Characteristics
electronic Medicines Compendium, 2026
1 tablet
1.000 whole tablet(s) every 12 hours for 25.00–50.00 kg dogs. This band spans 20 to 10 mg/kg amoxicillin; the upper exposure is reserved by the veterinary comparator for refractory respiratory infection. The exact human tablet is not an equal-dose divider.
 Dog 25–50 kg By mouth 2 times daily
Synulox tablets
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Synulox palatable tablets 200 mg/50 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
2 tablets
2.000 whole tablet(s) every 12 hours for 50.00–100.00 kg dogs. This band spans 20 to 10 mg/kg amoxicillin; the upper exposure is reserved by the veterinary comparator for refractory respiratory infection. The exact human tablet is not an equal-dose divider.
 Dog 50–100 kg By mouth 2 times daily
Synulox tablets
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Synulox palatable tablets 200 mg/50 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance doses, with sources
Active substance Amoxicillin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10 mg/kg Dog, Cat Bacterial Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Synulox palatable tablets 200 mg/50 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
20 mg/kg Dog Respiratory Tract Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Synulox Palatable Drops 40 mg/ml + 10 mg/ml, Powder for Oral Suspension - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
7 mg/kg Dog, Cat Bacterial Infection Subcutaneous once daily for up to 5 days
Betamox 150 mg/ml, VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Betamox 150 mg/ml Suspension for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Active substance Clavulanic Acid
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5 mg/kg Dog, Cat Bacterial Infection By mouth 2 times daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Synulox palatable tablets 200 mg/50 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical Amoxicillin
    Do not use in cases of hypersensitivity to the active substances, other substances of the beta-lactam group or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Amoxicillin
    Do not use in animals with severe renal impairment with anuria or oliguria.
    Sources: VMD SPC · VMD
  • Warning Amoxicillin
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
    Sources: VMD SPC · VMD
  • Warning Amoxicillin
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Amoxicillin + Doxycycline
    The bactericidal effect of amoxicillin may be inhibited by the concomitant use of bacteriostatic antimicrobials.
    Recommendation: If both are required, support the choice with culture and susceptibility results. Otherwise, choose one mechanism.
    Sources: VMD SPC · VMD
  • Major warning Amoxicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Minor warning Amoxicillin + Dihydrostreptomycin
    Penicillins may increase the effect of aminoglycosides.
    Recommendation: An enhanced effect is expected; monitor for aminoglycoside toxicity. Do not mix in the same syringe.
    Sources: VMD SPC · VMD
  • Minor warning Amoxicillin + Trimethoprim/Sulfonamide
    Concurrent use of bactericidal beta-lactam antibiotics and bacteriostatic antimicrobials such as sulfonamides is generally not recommended because their effects may be antagonistic.
    Recommendation: Avoid concomitant administration.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗